Predicting the effects of drugs before human clinical trials is at the heart of drug screening
and discovery processes. The cost of drug discovery is steadily increasing owing to the …

The cell microenvironment has emerged as a key determinant of cell behavior and function
in development, physiology, and pathophysiology. The extracellular matrix (ECM) within the …

Organoid models of early tissue development have been produced for the intestine, brain,
kidney and other organs, but similar approaches for the heart have been lacking. Here we …

Cardiovascular diseases (CVDs) constitute the prime cause of global mortality, with an
immense impact on patient quality of life and disability. Clinical evidence has revealed a …

Organ and tissue loss through disease and injury motivate the development of therapies that
can regenerate tissues and decrease reliance on transplantations. Regenerative medicine …

Despite increased use of human induced pluripotent stem cell-derived cardiomyocytes
(hiPSC-CMs) for drug development and disease modeling studies, methods to generate …

Improving the effectiveness of preclinical predictions of human drug responses is critical to
reducing costly failures in clinical trials. Recent advances in cell biology, microfabrication …

We report the fabrication of a scaffold (hereafter referred to as AngioChip) that supports the
assembly of parenchymal cells on a mechanically tunable matrix surrounding a perfusable …

Background: Tissue engineering enables the generation of functional human cardiac tissue
with cells derived in vitro in combination with biocompatible materials. Human-induced …

To curb the high cost of drug development, there is an urgent need to develop more
predictive tissue models using human cells to determine drug efficacy and safety in advance …